Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    51,728.93
    +1,762.72 (+3.53%)
     
  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Global Aspiration & Biopsy Needles Market Size, Share & Industry Trends Analysis Report By Product Type, By Procedure, By Image-guided Type, By End User, By Application, By Tumor/ Cancer Applications Type, By Regional Outlook and Forecast, 2022 - 2028

ReportLinker
ReportLinker

The Global Aspiration & Biopsy Needles Market size is expected to reach $1. 3 billion by 2028, rising at a market growth of 6. 1% CAGR during the forecast period. A biopsy is a surgical operation that involves removing tissue from an organ to detect the existence or degree of a disease, most commonly cancer and inflammatory disorders.

New York, June 10, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Aspiration & Biopsy Needles Market Size, Share & Industry Trends Analysis Report By Product Type, By Procedure, By Image-guided Type, By End User, By Application, By Tumor/ Cancer Applications Type, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06283396/?utm_source=GNW
Surgeons, radiologists, and interventional cardiologists are the most common practitioners. As a confirmatory test for cancer and celiac disease, biopsies can be conducted on any organ using specialized biopsy instruments. The type of organ under consideration determines how each biopsy equipment is used. Advanced imaging technologies, such as ultrasound-guided biopsy, MRI-guided biopsy, stereotactic-guided biopsy, CT scan, and others, can be used in conjunction with traditional biopsy techniques to perform a biopsy with accuracy and least invasiveness. Biopsies of body organs such as the liver, lungs, and kidneys are performed using these integrated methods.

Needle biopsy is a method of removing a sample of cells from the body by inserting a needle into the appropriate sampling area. The tissue is then examined in a laboratory to discover if it contains any abnormalities. A needle biopsy is used to determine the cause of symptoms such as a tumor, lump, inflammation, or infection. Computed tomography or ultrasound may be utilized in conjunction with a needle biopsy to provide more precise results.

To check anomalies at a specific location, radiologists and surgeons use biopsy needle techniques such as core-needle and fine-needle procedures. Increased demand for minimally invasive procedures, as well as cancer awareness programs run by governments and worldwide health organizations, are expected to drive market growth throughout the forecast period.

COVID-19 Impact

Cancer screening, cancer management visits, and cancer biopsy procedures have all decreased significantly as a result of the COVID-19 outbreak. Cancer screening services were hampered to some extent as a result of the lockdowns, which reduced the demand for biopsy needles. In a study conducted in the United Kingdom and published in Lancet Oncology in March 2021, the consequences of delayed cancer detection due to COVID-19 were studied. Over 90,000 patients with breast, colorectal, esophageal, or lung cancer were included in the study. It was discovered that the COVID-19 pandemic will have a significant impact on 1- and 5-year cancer survival rates because of a decrease in diagnostic biopsies and a lack of screening services.

Market Growth Factors

Rising Incidences of Cancer

There has been a spike in the number of people diagnosed with cancer around the world. This can be due to a variety of factors, including changes in lifestyle, bad diets, and increased cigarette use. According to the International Agency for Research on Cancer (IARC), 17.0 million new cancer cases and 9.5 million cancer deaths occurred globally in 2018. The global burden of cancer is anticipated to rise to 27.5 million new cases and 16.3 million deaths by 2040, owing to population expansion and aging.

Rising Demand in Emerging Countries

Disruptive business trends are expected as spanning from shifting supply chains to cost savings, automation, and a focus on customers. Companies that recognize and align their operations with industry trends will gain significant market share. In the aspiration and biopsy needles market, emerging markets such as India, China, Brazil, and Mexico are expected to provide considerable growth potential for competitors. This can be ascribed to increased healthcare expenditures, improved living conditions, a broad target population base, improved and expanded healthcare infrastructure, and modernization of healthcare research and facilities in these countries.

Market Restraining Factors

Reusing Aspiration and Biopsy Needles Poses Risk of Infection to Patients

Radiologists and surgeons use biopsy needle procedures such as core-needle and fine-needle procedures to examine anomalies at a specific spot. Patients may, however, get infections as a result of the cuts and incisions used to remove tissue samples. Furthermore, aspiration and biopsy needles are frequently reused, raising the infection risk during these procedures. Despite the fact that the reuse of some needles is discouraged by healthcare authorities and product manufacturers, the practice persists, particularly in developing nations.

Product Type Outlook

Based on Product Type, the market is segmented into Biopsy Needles and Aspiration Needles. The aspiration needles segment garnered a substantial revenue share in the aspirations and biopsy needles market in 2021. A fine needle aspiration operation is a sort of biopsy. A thin needle is introduced into a region of abnormal-appearing tissue or bodily fluid in fine needle aspiration. The sample collected during fine needle aspiration, like other forms of biopsies, can help make a diagnosis or rule out illnesses like cancer.

Procedure Outlook

Based on Procedure, the market is segmented into Image-guided and Nonimage-guided. Based on Image-guided Type, the market is segmented into Ultrasound-guided, CT-guided, MRI-guided, Stereotactic, and Others. The image-guided segment acquired the largest revenue share in the aspiration and biopsy needles market in 2021.This occurred due to the increasing demand for minimally invasive biopsy and aspiration procedures. Modern image-guided treatments, also known as image-guided surgical procedures, have been around for almost 30 years, starting with stereotactic brain surgery and gradually expanding to orthopedics, spinal surgery, heart surgery, and abdominal surgery. In order for an image-guided surgical platform to be successful, it must be able to localize and track the position of the surgical instrument or therapeutic device, register a localized volume with preoperative data, and give this information to the surgeon in an intuitive display. Preoperative data is frequently supplemented by intraoperative imaging.

End User Outlook

Based on End User, the market is segmented into Hospitals & surgical centers, Diagnostic Clinics & pathology laboratories, Ambulatory care centers, Research & Academic Institutes. The diagnostic clinics and pathology laboratories garnered a substantial revenue share in the aspiration and biopsy needles market in 2021. Clinicians use aspiration and biopsy needles to discover malignant growths and cardiac disorders such as atrial fibrillation. These needles can also be used for biopsies and aspirations of bone marrow. It is a diagnostic method in which cells or tissue samples are collected from various parts of the body in order to study them.

Application Outlook

Based on Application, the market is segmented into Tumor/ Cancer Applications, Wound Applications, and Others. Based on Tumor/ Cancer Applications Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Bone & Bone Marrow Cancer, and Others. The tumor/cancer segment acquired the largest revenue share in the aspiration and biopsy needles market in 2021. The rising incidence of breast cancer, greater awareness of the disease, and increased research activity relevant to breast screening and diagnosis are all factors contributing to this segment’s substantial proportion.

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The North American region acquired the largest revenue share in the aspiration and biopsy needles market in 2021. According to the American Cancer Society’s 2019 estimates for non-Hodgkin lymphoma, it was one of the most frequent malignancies in the United States, accounting for roughly 4% of all cancers. Lymphoma, a prevalent malignancy, raises the demand for biopsy needles as well. EUS biopsy needles have also undergone technological developments, which are expected to drive robust growth in the biopsy needles market throughout the forecast period.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Medtronic PLC, Johnson & Johnson, Merit Medical Systems, Inc., Cardinal Health, Inc., Becton, Dickinson and Company, ConMed Corporation, Olympus Corporation, Argon Medical Devices, Inc., and Cook Medical, Inc.

Strategies deployed in Aspiration & Biopsy Needles Market

May-2021: Olympus received FDA approval for BF-UC190F endobronchial ultrasound (EBUS) bronchoscope, a new addition to the company’s strong EBUS portfolio of devices. The device is meant to be utilized for minimally invasive lung cancer diagnosis and staging via needle biopsy.

Sep-2018: Olympus received FDA approval for its EZ Shot 3 Plus 25 G needle, a single-use endoscopic ultrasound needle. Through this approval, Olympus expanded its product line-up for both fine needle aspiration (FNA) and fine needle biopsy (FNB).

Scope of the Study

Market Segments covered in the Report:

By Product Type

• Biopsy Needles

• Aspiration Needles

By Procedure

• Image-guided

o Ultrasound-guided

o CT-guided

o MRI-guided

o Stereotactic

o Others

• Nonimage-guided

By End User

• Hospitals & surgical centers

• Diagnostic Clinics & pathology laboratories

• Ambulatory care centers

• Research & Academic Institutes

By Application

• Tumor/ Cancer Applications

o Breast Cancer

o Lung Cancer

o Colorectal Cancer

o Prostate Cancer

o Kidney Cancer

o Bone & Bone Marrow Cancer

o Others

• Wound Applications

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

• LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Boston Scientific Corporation

• Medtronic PLC

• Johnson & Johnson

• Merit Medical Systems, Inc.

• Cardinal Health, Inc.

• Becton, Dickinson and Company

• ConMed Corporation

• Olympus Corporation

• Argon Medical Devices, Inc.

• Cook Medical, Inc.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06283396/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001